Kidney transplant study tests vaccine booster strategy

NCT ID NCT05060991

Ongoing Knowledge-focused Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether temporarily reducing immunosuppressive medication can help kidney transplant recipients mount a stronger immune response to a third dose of the COVID-19 mRNA vaccine. Fourteen participants with low or no antibodies will have their antimetabolite dose lowered before and after vaccination. The goal is to see if this improves antibody levels while monitoring for organ rejection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: reduction in antimetabolite immunosuppression (mycophenolate mofetil/mycophenolic acid or azathioprine)
What this could lead to: If successful, this could point toward a way to improve vaccine protection for immunocompromised kidney transplant recipients.
What could go wrong: This is a very small early-phase study with only 14 participants, so results may not apply broadly. Lowering immunosuppression carries a risk of organ rejection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 IMMUNOSUPPRESSION VACCINE RESPONSE IMPAIRED

Contacts and locations

Locations

University of California, Davis

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.